Published Proposals
Access to clinical trial data provides opportunities to conduct further research that can help advance medical science or improve patient care. This helps ensure the data provided by research participants are used to maximum effect in the creation of knowledge and understanding.
Proposal number
|
Sponsor/Funder
|
Title
|
Lead researcher
|
|
631
|
GSK
|
Predictors of BPH Progression
|
Dr. Stephen Freedland, MD
|
Further Details
|
647
|
GSK
|
Assessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical Trials
|
David M. Kent, MD, MSc
|
Further Details
|
651
|
GSK
|
Descriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children.
|
Thomas Verstraeten
|
Further Details
|
669
|
GSK
|
A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - efficacy and adverse outcomes.
|
Jon Jureidini
|
Further Details
|
674
|
GSK
|
Antiepileptic drug monotherapy for epilepsy: an overview of systematic reviews and
network meta-analysis
|
Antony Marson
|
Further Details
|
911
|
GSK
|
Outcome Measures in Systemic Lupus Erythematosus: Constructing a Meaningful Response Index from Existing Clinical Trial Data
|
Lindsy Forbess, MD, MSc
|
Further Details
|
930
|
GSK
|
MASTERMIND: Stratification of glycaemic response the ADOPT and RECORD studies
|
Professor Andrew Hattersley, M.D. FRS
|
Further Details
|
945
|
ViiV
|
THE CD4/CD8 RATIO AS A PREDICTOR OF NON-AIDS EVENTS DURING ANTIRRETROVIRAL THERAPY: CONFIRMATION OF ITS PREDICTIVE VALUE AND IMPACT OF MARAVIROC IN TREATMENT-EXPERIENCED PATIENTS
|
Santiago Moreno
|
Further Details
|
946
|
GSK, Roche
|
Assessing models for changes in tumour size over time and how they relate to survival times.
|
Raluca Eftimie
|
Further Details
|
977
|
GSK
|
The implication of central adjudication of COPD exacerbations by experts for treatment effect estimates and sample size calculation
|
Milo Puhan
|
Further Details
|